Cambrex (CBM) Announces Earnings Results

Cambrex (NYSE:CBM) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.17, Bloomberg Earnings reports. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The business had revenue of $182.28 million for the quarter, compared to analyst estimates of $181.39 million. During the same quarter in the prior year, the firm posted $1.23 earnings per share. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. Cambrex updated its FY18 guidance to $2.80-3.03 EPS.

Cambrex (CBM) opened at $51.80 on Friday. Cambrex has a one year low of $42.55 and a one year high of $62.95. The stock has a market capitalization of $1,678.47, a price-to-earnings ratio of 16.87, a PEG ratio of 1.20 and a beta of 2.38.

CBM has been the topic of several research reports. Craig Hallum reaffirmed a “buy” rating and set a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. Finally, William Blair initiated coverage on Cambrex in a research note on Tuesday, January 16th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $60.00.

Institutional investors and hedge funds have recently modified their holdings of the company. Stifel Financial Corp lifted its stake in shares of Cambrex by 0.8% during the second quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 37 shares during the period. Piedmont Investment Advisors LLC acquired a new position in shares of Cambrex during the second quarter valued at $421,000. Tributary Capital Management LLC lifted its stake in shares of Cambrex by 22.3% during the third quarter. Tributary Capital Management LLC now owns 232,919 shares of the biotechnology company’s stock valued at $12,811,000 after acquiring an additional 42,428 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Cambrex by 117.0% during the third quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock valued at $12,721,000 after acquiring an additional 125,062 shares during the period. Finally, California Public Employees Retirement System lifted its stake in shares of Cambrex by 4.4% during the second quarter. California Public Employees Retirement System now owns 73,500 shares of the biotechnology company’s stock valued at $4,392,000 after acquiring an additional 3,100 shares during the period.

TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2018/02/10/cambrex-cbm-announces-earnings-results.html.

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Earnings History for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit